These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32493335)

  • 41. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
    Kishimoto S; Kinoshita Y; Matsumoto T; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Takaeko Y; Kihara Y; Chayama K; Goto C; Mohamad Yusoff F; Nakashima A; Noma K; Higashi Y
    Am J Hypertens; 2019 Jun; 32(7):695-702. PubMed ID: 31045223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 43. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
    Takeuchi K; Fujita T; Hiroi S
    Nihon Yakurigaku Zasshi; 2011 Jan; 137(1):43-50. PubMed ID: 21233588
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
    Takebayashi K; Sakurai S; Suzuki T; Hori K; Terasawa T; Naruse R; Hara K; Suetsugu M; Tsuchiya T; Aoki H; Hamasaki T; Shuutou H; Inukai T
    Endocr J; 2014; 61(10):1031-9. PubMed ID: 25185672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
    Guthrie R
    Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
    Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
    JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
    Nakamura Y; Inagaki M; Shimizu T; Fujita K; Inoue M; Gotoh H; Oguchi K; Goto Y
    Nephron Clin Pract; 2013; 123(1-2):46-51. PubMed ID: 23774306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Saxagliptin, alogliptin, and cardiovascular outcomes.
    White WB; Zannad F
    N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 51. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).
    Vaduganathan M; White WB; Charytan DM; Morrow DA; Liu Y; Zannad F; Cannon CP; Bakris GL;
    Am J Cardiol; 2019 Feb; 123(3):382-391. PubMed ID: 30477800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 56. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention.
    Zhang DW; Wang SL; Wang PL; Du JP; Gao ZY; Wang CL; Xu H; Shi DZ
    J Ethnopharmacol; 2020 Feb; 248():112354. PubMed ID: 31689480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alogliptin benzoate for the treatment of type 2 diabetes.
    Seino Y; Yabe D
    Expert Opin Pharmacother; 2014 Apr; 15(6):851-63. PubMed ID: 24646052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
    Muskiet MHA; Tonneijck L; Huang Y; Liu M; Saremi A; Heerspink HJL; van Raalte DH
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):859-869. PubMed ID: 30292589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
    Udell JA; Bhatt DL; Braunwald E; Cavender MA; Mosenzon O; Steg PG; Davidson JA; Nicolau JC; Corbalan R; Hirshberg B; Frederich R; Im K; Umez-Eronini AA; He P; McGuire DK; Leiter LA; Raz I; Scirica BM;
    Diabetes Care; 2015 Apr; 38(4):696-705. PubMed ID: 25552421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
    Negro R; Greco EL; Greco G
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):215-219. PubMed ID: 29558784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.